FAQs

We specialise in Alzheimer’s disease and other neurodegenerative disorders, including rare 4R tauopathies (PSP, CBD) and alpha-synucleinopathies (Parkinson’s disease, multiple system atrophy). We also support other dementia syndromes such as Lewy body dementia and frontotemporal lobar degeneration.

We work closely with all clinical sites to ensure every image is acquired according to protocol. Our team provides site training, verifies scanner settings, and monitors uploads in real time—delivering immediate feedback to maintain consistent, high-quality imaging data.

Yes. We support both standard and exploratory imaging endpoints, with extensive experience in novel tracers and early-phase clinical imaging research.

We support MRI, PET, CT, and SPECT—applying each modality with trial-specific imaging protocols to ensure consistent, actionable results.

We collect and manage all imaging data in a secure, centralised system—ensuring data integrity, quality control, and 21 CFR Part 11 compliance from start to finish.